Chris is responsible for oncology research as well as coverage of life sciences companies in China.
Prior to joining RTW, Chris spent 5 years in Business Development at GenScript, where he primarily worked on antibody drug discovery and development including novel immuno-oncology targets. He also worked on the design and optimization of CAR constructs for CAR-T companies such as Kite, Juno, and Bellicum.
We are in an era of groundbreaking innovation in bioscience. I am thrilled to be a part of the community trying to bring novel medicines to patients.
Chris received a PhD in Biochemistry from SUNY Stony Brook and a BS in Chemistry from Fudan University. He also received his MBA in Finance and Management from NYU Stern School of Business.